The EMCDDA receives stable funding under Commission budget line B3-441 of the general budget of the European Union. Each year, a preliminary draft budget is presented by the Centre's Director to the Management Board, which may modify the draft before adopting it and submitting it to the European...
Comorbidity of substance use and mental disorders in Europe
This publication looks at the co-occurrence of drug use problems and mental health disorders, taking in the theoretical background of psychiatric comorbidity, the tools for clinical diagnosis and the prevalence and clinical relevance of the problem in Europe.
Drugnet Europe 92
In this issue: Lisbon Addictions 2015 — conference round-up | Sponsored sessions at Lisbon Addictions 2015 | EMCDDA 20 years of monitoring conference | EMCDDA signs Memorandum of Understanding with Georgia | Minimum quality standards for drug demand reduction interventions in the EU | New EMCDDA...
Report on the risk assessment of 4,4′-DMAR in the framework of the Council Decision on new psychoactive substances
This publication presents the data and findings of the risk assessment on 4,4’-DMAR (4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine), carried out by the extended Scientific Committee of the EMCDDA on 16 September 2014. The main part of the publication, the Risk Assessment Report, examines...
Report on the risk assessment of MT-45 in the framework of the Council Decision on new psychoactive substances
This publication presents the data and findings of the risk assessment on MT-45 (1-cyclohexyl-4-(1, 2-diphenylethyl)piperazine), carried out by the extended Scientific Committee of the EMCDDA on 16 September 2014. The main part of the publication, the Risk Assessment Report, examines the health and...
20 years: Monitoring, Communicating evidence, Informing policy
In 2015, the EMCDDA commemorates 20 years of monitoring the drugs problem in Europe. This brochure provides a summary of the agency’s key achievements over the period, along with a timeline showing a selection of major events, presented per year.
EMCDDA–Europol Joint Report on a new psychoactive substance: 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (α-PVP)
In May 2015, the EMCDDA and Europol examined the available information on a new psychoactive substance 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone, commonly known as α-pyrrolidinovalerophenone (α-PVP), through a joint assessment. The two organisations concluded that sufficient information had been...
Problem drug use indicator (poster)
Some drug users go on to develop more severe forms of use, defined by the EMCDDA as ‘high-risk drug use’: ‘recurrent drug use that is causing actual harms (negative consequences) to the person (including dependence, but also other health, psychological or social problems) or is placing the person...
Tobacco in cannabis joints: why are we ignoring it? (poster)
General population survey data from EU Member States show that cannabis is the illicit drug most used by Europeans. The latest data show that an estimated 14.6 million young Europeans (aged 15–34) used cannabis in the last year, with 8.8 million of these aged 15–24. It is estimated that almost...
Drugs policy and the city in Europe (poster)
The European Union is one of the most urbanised areas in the world and its cities are set to become more densely populated. Currently 73 % of the EU population resides in cities and this is projected to increase to 82 % (or 30 million new residents) by 2050. The EMCDDA analysis Drugs policy and the...
Financing health and drug policy in the wake of the economic recession (poster)
The financial crisis that hit the global economy in the summer of 2007 has no precedent inpost-war economic history. It differed from other fluctuations in its magnitude and the degree to which it was synchronous around the world. In 2009, the world economy contracted, havingan overall GDP growth...
Ageing and addiction: challenges for treatment systems (poster)
Historically, problem opioid users, mainly injectors, have always represented the largest client group receiving specialised drug treatment in the European Union. The needs of large cohorts that started heroin injecting during the heroin ‘epidemics’ of 1980s and 90s have shaped and characterised...
New psychoactive substances in Europe (conference poster)
Since 1997, the EMCDDA has played a central role in Europe's response to new psychoactive substances. Its main responsibilities in this field are to operate the EU Early Warning System, with its partner Europol, and to undertake risk assessments of new substances when necessary. The EU Early...
Harms arising from the use of synthetic cannabinoid products (poster)
‘Synthetic cannabinoids’ or, more correctly, synthetic cannabinoid receptor agonists (SCRAs), are synthetic chemicals that mimic the effects of the natural psychoactive substances found in cannabis. ‘Legal high’ products containing SCRAs have been sold as herbal smoking mixtures since at least 2006...
Cannabis: what does the data tell us? (poster)
Cannabis is the illicit drug most likely to be used by all age groups. The drug is generally smoked and, in Europe, is commonly mixed with tobacco. Patterns of cannabis use can range from the occasional to the regular and dependent. This poster was created for the Lisbon Addictions Conference 2015...
Old dog, new tricks? Using opioid supply information for horizon scanning (poster)
Much attention is focused on the many new drugs emerging alongside the apparent decline in the use of established substances, such as heroin. In this globalised, inter-connected world the situation can change rapidly, problems can metamorphose and new challenges emerge. To keep pace with change it...
General population survey indicator (poster)
Knowledge of the extent and patterns of drug use in the general population, and their changes over time, is a key aspect in understanding the drug phenomenon in Europe and in monitoring progress towards EU and Member State policy targets. The General population survey (GPS) indicator provides...
Treatment demand indicator (poster)
Comparable and reliable information on the numbers and characteristics of those entering specialised drug treatment in EU Member States is essential for understanding the European drug problem. The EMCDDA has been collecting data on drug treatment entrants through the Treatment demand indicator (...
Drug-related deaths indicator (poster)
Drug use, in particular high-risk drug use, is one of the major causes of avoidable mortality among young people in Europe, both directly through overdose and indirectly through drug-related diseases, accidents, violence and suicide. The Drug-related deaths (DRD) indicator is one of a set of five...
Drug-related infectious diseases indicator (poster)
Drug-related infectious diseases (DRID) are among the most serious health consequences of drug use. The DRID indicator collects data on the extent of drug-related infections amongpeople who inject drugs. This group is a key population affected by blood-borne viruses — primarily human...